PMVP Share Price | PMV Pharmaceuticals, Inc. Stock Analysis & Recommendation

Q: How big is PMV Pharmaceuticals, Inc.?

Market Cap: As of Jun 18, PMV Pharmaceuticals, Inc. has a market capitalization of 56.63 million, categorizing it as a Micro Cap company.Recent Quarterly Performance: For the latest four quarters, PMV Pharmaceuticals, Inc. reported net sales of 0.00 million and a net profit of -60.88 million.Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 176.08 million and total assets of 191.29 million.

Q: What does PMV Pharmaceuticals, Inc. do?

Overview: PMV Pharmaceuticals, Inc. is a precision oncology company focused on discovering and developing small molecule, tumor-agnostic therapies targeting p53 mutations, operating within the Miscellaneous industry and classified as a micro-cap company.Financial Snapshot: Most recent Net Profit: -17 Million (Quarterly Results - Mar 2025) Market cap: USD 56.63 Million (Micro Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -1.00 Return on Equity: -38.02% Price to Book: 0.35Contact Details: Address: 8 Clarke Drive, CRANBURY NJ: 08512 Tel: 1 609 6426664 Fax: 1 302 6365454 Website: http://pmvpharma.com/

Q: Is PMV Pharmaceuticals, Inc. technically bullish or bearish?

As of 10 September 2025, the technical trend for PMV Pharmaceuticals, Inc. has changed from bullish to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish, indicating some positive momentum. The daily moving averages are also mildly bullish. However, the weekly Dow Theory shows a mildly bearish stance, which contrasts with the monthly view that is mildly bullish. The Bollinger Bands present a mixed signal, being mildly bullish on the weekly and bearish on the monthly. Overall, the indicators suggest a mildly bullish stance, but the stock has underperformed significantly compared to the S&P 500, with a year-to-date return of -18.54% versus the S&P's 12.22%.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

73.44 k

Shareholding (Dec 2025)

FII

2.98%

Held by 36 FIIs

DII

64.65%

Held by 23 DIIs

Promoter

14.33%

How big is PMV Pharmaceuticals, Inc.?

22-Jun-2025

As of Jun 18, PMV Pharmaceuticals, Inc. has a market capitalization of 56.63 million, with net sales of 0.00 million and a net profit of -60.88 million over the latest four quarters. The company reported shareholder's funds of 176.08 million and total assets of 191.29 million as of Dec 24.

View full answer

What does PMV Pharmaceuticals, Inc. do?

22-Jun-2025

PMV Pharmaceuticals, Inc. is a precision oncology company developing small molecule therapies targeting p53 mutations. It has a market cap of $56.63 million and reported a net profit loss of $17 million as of March 2025.

View full answer

Who are in the management team of PMV Pharmaceuticals, Inc.?

22-Jun-2025

As of March 2022, the management team of PMV Pharmaceuticals, Inc. is led by Dr. David Mack, who is the President, Chief Executive Officer, Co-Founder, and Director.

View full answer

Is PMV Pharmaceuticals, Inc. technically bullish or bearish?

20-Sep-2025

As of September 10, 2025, PMV Pharmaceuticals, Inc. shows a mildly bullish trend overall, with mixed signals from various indicators, but has significantly underperformed the S&P 500 with a year-to-date return of -18.54%.

View full answer

Compare PMV Pharmaceuticals, Inc. with Similar Stocks

Emerald Holding, Inc.Paymentus Holdings, Inc.Acacia Research Corp.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Miscellaneous

Market cap

USD 83 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.06

Return on Equity

-68.35%

Price to Book

0.69

Revenue and Profits:

Net Sales:

(Quarterly Results - Dec 2025)

Net Profit:

-18 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

5.65%

6 Months

-11.49%

1 Year

13.91%

2 Years

-20.61%

3 Years

-74.06%

4 Years

-93.48%

5 Years

-96.1%

PMV Pharmaceuticals, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

-197.85%

EBIT to Interest (avg)

-69.74

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.00

Sales to Capital Employed (avg)

Tax Ratio

23.11%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

92.73%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

0.69

EV to EBIT

0.50

EV to EBITDA

0.50

EV to Capital Employed

5.81

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

1172.03%

ROE (Latest)

-68.35%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bullish

Mildly Bullish

RSI

Bearish

No Signal

Bollinger Bands

Mildly Bullish

Bearish

Moving Averages

Mildly Bearish (Daily)

KST

Bullish

Mildly Bullish

Dow Theory

Mildly Bearish

Mildly Bullish

OBV

Mildly Bearish

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 22 Schemes (18.05%)

Foreign Institutions

Held by 36 Foreign Institutions (2.98%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 21.74% vs -45.57% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-19.20",
          "val2": "-25.10",
          "chgp": "23.51%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-18.00",
          "val2": "-23.00",
          "chgp": "21.74%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is -32.37% vs 14.93% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-86.10",
          "val2": "-84.30",
          "chgp": "-2.14%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-77.70",
          "val2": "-58.70",
          "chgp": "-32.37%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY

Dec'25

Dec'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-19.20

-25.10

23.51%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-18.00

-23.00

21.74%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in quarter ended Dec 2025 is 21.74% vs -45.57% in Dec 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-86.10

-84.30

-2.14%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-77.70

-58.70

-32.37%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is -32.37% vs 14.93% in Dec 2024

All Annual Results

Company CV

About PMV Pharmaceuticals, Inc.

PMV Pharmaceuticals, Inc.

Miscellaneous

PMV Pharmaceuticals, Inc. is a precision oncology company. The Company is focused on discovering and developing small molecule, tumor-agnostic therapies targeting p53 mutations. It’s lead product candidate, PC14586, is designed to potently and selectively correct p53 misfolding caused by a specific p53 mutation, Y220C, while sparing wild-type p53. It is also using its precision oncology platform to develop a pipeline of oral small molecule product candidates that structurally correct other p53 hotspot mutations to restore their wild-type function. Its second program, R273H, targets the p53 R273H hotspot mutation.

Company Coordinates

Company Details

8 Clarke Drive , CRANBURY NJ : 08512

Tel: 1 609 6426664

http://pmvpharma.com/

Registrar Details